AtaiBeckley Inc.
ATAI · Pharmaceutical Preparations · 368.2M shares · EDGAR filings ↗
Reference price $5.00 · est. market cap ~$1.8B — last insider sale, 2026-04-20 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — psychedelics clinical, heavy burn ($104M), funded.
Strengths
- Liquidity — current ratio 11.7 (83rd)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Net lossNet loss (net margin -16142.0%)
- Cash burnNegative free cash flow (-103.6M)
- Fund exitedNotable fund(s) exited this quarter: ARK Investment Management LLC
- Exec changeRecent 8-K item 5.02 8-K ↗
- New fund positionNotable fund(s) opened this quarter: STATE STREET CORP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC
- Insider sellingInsider selling — 3 open-market sale(s) by 2 insider(s) (cluster of 2 insiders, ~$722,272, last 6mo) Form 4 ↗
- Revenue declineRevenue -38.6% YoY
- Notable holderHeld by 3 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC (as of 2026-03-31)
- AccumulatingInstitutional holders rose 1→7 QoQ (2025-12-31→2026-03-31)
Quarterly revenue
Last 2 quarters · from SEC filings.
Key metrics
Operating margin
-15751.1%
Net margin
-16142.0%
Return on equity
-297.5%
Return on assets
-225.5%
ROIC
-229.3%
Revenue growth (QoQ)
-38.6%
Debt / equity
0.0×
Current ratio
11.7×
Free cash flow
-$104M
EBITDA
-$643M
Tangible book value
$219M
Cash & investments
$85M
Cash runway
3q
Stock comp / revenue
347.6%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-20 | Craig Kevin James | Option exercise | 27K | $1.50 |
| 2026-04-20 | Craig Kevin James | Option exercise | 15K | $1.84 |
| 2026-04-20 | Craig Kevin James | Sell | 43K | $5.00 |
| 2026-04-08 | Angermayer Christian | Option exercise | 46K | $1.88 |
| 2026-04-08 | Angermayer Christian | Option exercise | 410K | $1.64 |
| 2026-04-08 | Angermayer Christian | Option exercise | 103K | $1.34 |
| 2026-03-20 | Craig Kevin James | Option exercise | 76K | $1.18 |
| 2026-03-20 | Craig Kevin James | Option exercise | 24K | $1.50 |
| 2026-03-20 | Craig Kevin James | Sell | 100K | $3.55 |
| 2026-01-02 | Feilding-Mellen Cosmo | Sell | 40K | $3.90 |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-08 | 2026-06-04 | 0001140361-26-024474 ↗ |
| 8-K | 2026-06-03 | 2026-06-03 | 0001140361-26-023815 ↗ |
| 10-Q | 2026-05-12 | 2026-03-31 | 0001193125-26-219412 ↗ |
| 8-K | 2026-05-12 | 2026-05-12 | 0001140361-26-020708 ↗ |
| 8-K | 2026-03-09 | 2026-03-09 | 0001140361-26-008354 ↗ |
| 10-K | 2026-03-06 | 2025-12-31 | 0001193125-26-096926 ↗ |
| 8-K | 2026-03-06 | 2026-03-06 | 0001140361-26-008296 ↗ |
| 8-K | 2026-03-06 | 2026-03-06 | 0001140361-26-008178 ↗ |
| 8-K | 2026-02-26 | 2026-02-26 | 0001140361-26-006880 ↗ |
| 8-K | 2026-02-19 | 2026-02-15 | 0001140361-26-006118 ↗ |
| 8-K | 2026-01-08 | 2026-01-06 | 0001140361-26-000614 ↗ |